Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Previous indications for Leronlimab
- Leronlimab is a CCR5 receptor antagonist
- CCR5 receptor function in inflammation and disease
- Clinical limitations of blocking CCR5 receptors
- How will Leronlimab be used in the clinic?
- When can we expect a preliminary approval?
- **We are informed that key findings were submitted for publication on 24 April 2020 **
Biography
Jacob P. Lalezari, M.D., is the Medical Director of Quest Clinical Research in San Francisco, California, and interim Chief Medical Officer of CytoDyn, providing leadership for the COVID-19 Leronlimab clinical trials. Since 1989, Dr. Lalezari has been a Principal Investigator for all phases of clinical trials testing new antiviral therapies and/or vaccines for HIV/AIDS, Cytomegalovirus, Herpes Simplex Virus, Hepatitis B & C, Human Papilloma Virus, Respiratory Syncytial Virus, Influenza Virus and SARS-CoV-2.
Dr. Lalezari’s work has been published in peer-reviewed journals such as New England Journal of Medicine, Journal of Infectious Diseases and Annals of Internal Medicine. He received his M.D. in Internal Medicine from the University of Pennsylvania and holds a M.A. in English Literature from the University of Virginia.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Lalezari, J. (2020, April 21). Development of PRO-140 (Leronlimab) as a treatment for COVID-19 [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2024, from https://doi.org/10.69645/JEML7811.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jacob Lalezari has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)